Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study
| Autor: | Sarvenaz Salahi, Vajiheh Aghamollaii, Nikta Nikbakht, Nahid Noruzi, Rezvan Noruzzadeh, Majid Ghaffarpour, Abbas Tafakhori, Mohammad Hossein Harirchian, Amirhossein Modabbernia |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Migraine without Aura Adolescent Nausea Placebo-controlled study Iran Placebo Severity of Illness Index Drug Administration Schedule law.invention 03 medical and health sciences Disability Evaluation Young Adult 0302 clinical medicine Randomized controlled trial Double-Blind Method law Memantine Severity of illness medicine Humans 030212 general & internal medicine Aged Psychiatric Status Rating Scales business.industry Middle Aged medicine.disease Treatment Outcome Neurology Migraine Tolerability Anesthesia Female Neurology (clinical) medicine.symptom business Excitatory Amino Acid Antagonists 030217 neurology & neurosurgery medicine.drug Follow-Up Studies |
| Zdroj: | Headache. 56(1) |
| ISSN: | 1526-4610 |
| Popis: | Background Uncontrolled studies in human have suggested that memantine might be a suitable option for migraine prophylaxis. Objective To assess the efficacy and tolerability of memantine for migraine prophylaxis. Methods This was a 12-week randomized double-blind placebo-controlled parallel-group study. Sixty patients with migraine without aura were randomized using a computer-generated list to receive memantine (10 mg/day) or placebo for 12 weeks. The primary outcome was the difference in change from baseline in the monthly attack frequency at week 12 between the two groups (using migraine diary). Secondary efficacy measures were assessed using several clinical, functional, and psychological instruments. We performed both complete case (CC) and intention-to-treat analyses (ITT). Results Twenty-five patients in the memantine group and 27 patients in the placebo group completed the study. Patients in the memantine group showed significantly greater reduction (mean change; 3.4; 95%CI, 2.3-4.4) in the monthly attack frequency than the placebo group (mean change, 1.0; 95%CI, 0.3-1.7) (mean difference [MD], 2.3; 95%CI, 1.1-3.5, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text